HOPE & RELIEF

Spravato is an exciting new treatment option providing relief for those suffering from depression that is FDA Approved and covered by most insurances.

You Can Find Relief Today!

Take The First Step Below

Learn More About Spravato

Esketamine nasal spray, also known as Spravato, is an FDA-approved intranasal spray that can be prescribed to help patients with treatment-resistant depression along with an antidepressant.

Not only is Spravato potentially rapid-acting, but it is the first truly new mechanism for depression that has been approved by the FDA in over 60 years. This drug is intended to be used for people with major depression who have not responded well to at least two antidepressants.

Andala providers may recommend prescribing Spravato as part of your treatment plan. Nasal esketamine is related to ketamine, a safe, FDA-approved anesthetic that has been effective in the treatment of depression when used off-label in low-dose ketamine infusion therapy.

Spravato, a nasal spray version of ketamine, works by inhibiting the NMDA (N-methyl-D-asparate glutamate) receptor. While Spravato has been demonstrated in multiple clinical trials to be an effective treatment for treatment-resistant depression (TRD), it is not known how exactly Spravato works to treat this depressive disorder. Spravato must be prescribed by a medical professional, and patients self-administer the treatment in our clinic under medical supervision.

Call Now